Genitourinary Syndrome

Vaginal estrogen, vaginal dehydroepiandrosterone, oral ospemifene and vaginal moisturizers result in short-term improvements in vaginal atrophy symptoms, known as genitourinary syndrome of menopause, but more long-term data are needed.

At 12 weeks, vaginal hyaluronic acid and vaginal estrogen were associated with similar benefits in the treatment of atrophic vaginitis, known as genitourinary syndrome of menopause, according to results of a pilot trial.

Postmenopausal women assigned daily oral lasofoxifene had significant and clinically meaningful improvements in vulvovaginal atrophy symptoms with a favorable safety profile, researchers reported in Menopause.

Menopausal women experience multiple vulvovaginal symptoms with variations in quantity, severity and frequency, which cause significant interference in daily life, according to a post hoc analysis published in Menopause.

Estradiol cream applied to the vulvar vestibule plus precoital silicone lubricant may offer an alternative to vaginal therapy for women with dyspareunia, according to a randomized pilot trial published in Menopause.

Postmenopausal women with moderate to severe genitourinary syndrome experienced small but significant increases in serum estradiol after using vaginal estradiol tablets for 12 weeks, according to a post hoc analysis in JAMA Network Open.

Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, according to an updated position statement from the North American Menopause Society.

Among postmenopausal women, CO2-laser therapy was a “safe energy-based therapeutic option” for management of the genitourinary syndrome of menopause; however, the quality of evidence is “very low or low,” researchers wrote.